LAKAN INJECTION 1% (10ML VIAL)

Country: Malaysia

Language: English

Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Active ingredient:

LIGNOCAINE/LIDOCAINE

Available from:

DUOPHARMA (M) SDN. BHD.

INN (International Name):

LIGNOCAINE/LIDOCAINE

Units in package:

10 ml 10 Units mL; 10 ml 25 Units mL; 10 ml 100 Units mL

Manufactured by:

DUOPHARMA (M) SDN. BHD.

Summary of Product characteristics

[DUOPHARMA (M) SDN BHD]
NOT FOR INTRAVENOUS USE
[Page 1/2]
[Revision Date: (15.08.2020]
LAKAN INJECTION
COMPOSITION:
LAKAN INJECTION 1% (10 ML VIAL): Each vial contains Lignocaine
Hydrochloride 100 mg per 10 ml
LAKAN INJECTION 2% (10 ML VIAL): Each vial contains Lignocaine
Hydrochloride 200 mg per 10 ml
Preservative: Methyl Paraben 0.1% w/v
DESCRIPTION: LAKAN INJECTION is a clear, colourless liquid.
PHARMACODYNAMICS:
Class:
Local anaesthetic of the amide type and antiarrhythmic drug.
Lignocaine stabilizes all potentially excitable membranes and prevents
the
initiation and transmission of nerve impulses. This produces a local
anaesthetic effect. Onset of action is rapid and blockade may last
from 1-1½
hours. In cardiac tissue, a therapeutic serum concentration (1.5 to
6.0 mcg / mL) of lignocaine will produce the following effects.
1.
Depression of slow spontaneous depolarization (phase 4), that is the
automaticity of isolated, non-polarised Purkinje fibres, while having
little
effect on conduction velocity, membrane responsiveness or cardiac
output. Automaticity induced by stretch, hypoxia or catecholamines can
also
be
suppressed by lignocaine.
2.
Shortening of the action potential period and the effective refractory
period of Purkinje and ventricular cells. The effective refractory
period is not
reduced to the same extent, however, and the ratio of effective
refractory period to action potential duration is increased.
3.
In the presence of high extracellular potassium ion concentrations, or
in myocardial ischaemia where the cells are partially depolarized,
lignocaine
depresses the membrane responsiveness and conduction velocity in
Purkinje fibres and the myocardium.
PHARMACOKINETICS:
ABSORPTION: COMPLETE SYSTEMIC ABSORPTION: The rate of absorption is
influenced by the site and route of administration, total dosage
administered,
physical characteristics of the individual agent, and whether or not a
vasodilator is used concurrently.
BIOTRANSFORMATION: LIGNOCAINE: Xylidine metabolites are active and
toxic, but less